데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer

데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer

데일리팜 리크루트 intelligence: Vyloy (zolbetuximab) has passed the HIRA Pharmacoeconomic Evaluation Subcommittee and is set for Drug Reimbursement Evaluation Committee review. This analysis covers the clinical evidence, regulatory milestones, and strategic implications for pharma stakeholders — a targeted brief for BD teams, investors, and analysts tracking Korea's shifting gastric cancer reimbursement terrain.

Key Takeaways

• Vyloy cleared the HIRA Pharmacoeconomic Evaluation Subcommittee on May 22, 2026, and faced the Drug Reimbursement Evaluation Committee on June 4, 2026 — breaking a stall that followed its initial Cancer Drug Review Committee passage in October 2025, per DailyPharm Korea.
• The drug is a claudin 18.2-directed cytolytic antibody approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for first-line CLDN18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, per the FDA label — one of the few biomarker-driven options in a high-incidence market.
BD teams and investors should watch final pricing negotiations, competitive pressure from other CLDN18.2 programs, and a maturing diagnostic ecosystem, supported by practical management guidance from the Project VYLOY Initiative and a 2026 diagnostic reproducibility study in PubMed.

What Changed in Vyloy's Reimbursement Path?

Astellas Pharma Korea secured approval for Vyloy in September 2024, but the reimbursement route then hit a wall. The Cancer Drug Review Committee signed off in October 2025, yet no further progress emerged until late May 2026. On May 22, the Health Insurance Review & Assessment Service's Pharmacoeconomic Evaluation Subcommittee handed down a favorable assessment. On June 4, the Drug Reimbursement Evaluation Committee took up the case, according to DailyPharm Korea. Astellas appears to have addressed whatever cost-effectiveness objections had been holding things up — at least enough to satisfy the subcommittee — and the DREC review signals that HIRA is now weighing national formulary listing in earnest.

The therapy targets claudin 18.2, a tight-junction protein overexpressed in roughly a third of advanced gastric cancers. The FDA label defines Vyloy as a claudin 18.2-directed cytolytic antibody indicated, alongside fluoropyrimidine- and platinum-containing chemotherapy, for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors test CLDN18.2 positive. That biomarker requirement makes patient selection hinge on reliable, standardized diagnostic testing — a point the research community has been working to lock down.

The SPOTLIGHT and GLOW Phase III trials provided the efficacy data that underpinned global approvals. Korean regulators saw the same data package, and the DREC review now suggests HIRA is prepared to move from clinical evaluation to access negotiation.

Why Does This Matter for Pharma BD and Investors?

A positive DREC outcome would unlock national reimbursement in a country with one of the world's highest gastric cancer incidence rates. That translates into a commercially meaningful addressable population for Astellas and, just as important, sets a pricing benchmark that every other CLDN18.2 program will have to cite. HIRA typically negotiates discounts in the 20–40% range for innovative oncology biologics, so the final contract price will signal how Korean payers value biomarker-directed therapies against conventional platinum-based doublets.

BD teams should map the competitive landscape now. Vyloy holds first-mover advantage in the CLDN18.2 space, but chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates targeting the same antigen are advancing through Phase II and III trials globally. A DREC approval would also pressure hospital pharmacy and supply-chain teams to prepare for infusion-based therapy delivery — and that means staffing up. 팜 리쿠르트 구인구직 and 약사 공론 구인구직 have become go-to channels for oncology-trained clinical pharmacists and market-access specialists, while 데일리팜 부동산 captures the facility-lease activity that accompanies operational scale-up for launch-ready biopharma teams.

For investors, the next six months are the critical window. Reimbursement volume projections, the scope of the covered indication, and whether HIRA imposes a coverage-with-evidence-development requirement will all shape revenue estimates for Asia's second-largest pharma market. The broader claudin-targeting field is also accelerating: a review published May 28, 2026, in PubMed titled "Targeting claudins in cancer" surveys the mechanistic rationale and pipeline landscape, reinforcing that CLDN18.2 is no niche play. 데일리팜 리크루트 continues to track these developments as a resource for hiring managers and deal teams alike.

What Diagnostics and Management Infrastructure Is Taking Shape?

Reimbursement alone does not guarantee adoption. Prescribers need standardized, reproducible companion diagnostics to identify eligible patients, and infusion centers need clear protocols for administration and adverse-event monitoring. Both gaps are being addressed.

On the diagnostic side, a 2026 study in PubMed on "Claudin 18.2 Expression in Gastric Adenocarcinoma: Diagnostic Reproducibility and Clinicopathologic Associations in a Western Cohort" confirmed that immunohistochemistry-based CLDN18.2 testing can deliver consistent results across laboratories — a prerequisite for confident patient selection and payer acceptance. Without that standardization, oncologists hesitate to order the test, and payers push back on biomarker-driven indications.

On the clinical management side, the Project VYLOY Initiative published practical guidance in June 2025, available via PubMed, covering infusion protocols, premedication strategies, and adverse-event monitoring. These are the operational details that hospital formulary committees and pharmacy directors demand before adding a new biologic to their regimen. For Astellas's market-access team in Korea, having these guidelines in hand strengthens the reimbursement dossier and shortens the time from DREC approval to first patient dosed. The 팜 리쿠르트 구인구직 ecosystem has already seen upticks in listings for oncology clinical pharmacists and biomarker operations leads — a leading indicator that institutions expect volume.

Together, the diagnostic reproducibility data and the management playbook reduce the friction that typically slows biomarker-driven launches. That is good news for Astellas and for the BD teams evaluating partnership or co-promotion opportunities in Korea, where staffing depth — tracked through 데일리팜 리크루트 and 약사 공론 구인구직 — remains a reliable signal of launch readiness.

Frequently Asked Questions

Related profiles

• VYLOY
• zolbetuximab